BioScience Health Innovations (BHICD) Financials
Newest figures come from the 10-Q for Q1 FY2026, filed May 11, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BHICD SEC filings page.
BioScience Health Innovations Inc (BHICD) reported $5.2M in revenue over the twelve months to Mar 31, 2026, up 86.5% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
BHICD has shifted from losses to profitable scale, but working-capital growth limits cash conversion.
From FY2024 to FY2025, revenue grew208.3% while gross margin fell14.0 percentage points . Operating margin nevertheless rose7.9 percentage points , implying overhead was absorbed more efficiently even as direct costs consumed more sales.
FY2025 net income was
Liabilities were
Financial Health Signals
We do not publish a peer-relative financial health score for BioScience Health Innovations Inc, because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
BioScience Health Innovations Inc passes 5 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 3 of 4 profitability signals pass, all 1 leverage/liquidity signals pass, 1 of 2 operating efficiency signals passes.
For every $1 of reported earnings, BioScience Health Innovations Inc generates $0.27 in operating cash flow ($172K OCF vs $642K net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
BioScience Health Innovations Inc generated $751K in revenue in Q1 2026. This represents a decrease of 38.8% from the same quarter a year earlier. Against the prior quarter it is down 52.3%.
BioScience Health Innovations Inc reported a net loss of $230K in Q1 2026. This represents a decrease of 153.9% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
BioScience Health Innovations Inc earned -$0.02 per diluted share (EPS) in Q1 2026.
Not reported for Q1 2026.
Cash & Balance Sheet
BioScience Health Innovations Inc held $1.1M in cash as of Q1 2026; no long-term debt figure is on record for that period.
Not reported for Q1 2026.
Not reported for Q1 2026.
Margins & Returns
BioScience Health Innovations Inc's gross margin was 64.7% in Q1 2026, indicating the percentage of revenue retained after direct costs. This is down 8.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 28.3 percentage points.
BioScience Health Innovations Inc's operating margin was -30.6% in Q1 2026, reflecting core business profitability. This is down 65.4 percentage points from the same quarter a year earlier. Against the prior quarter it is down 20.7 percentage points.
BioScience Health Innovations Inc's net profit margin was -30.6% in Q1 2026, showing the share of revenue converted to profit. This is down 65.4 percentage points from the same quarter a year earlier. Against the prior quarter it is down 15.8 percentage points.
BioScience Health Innovations Inc's quarterly ROE was -13.7% in Q1 2026: one quarter's net income over shareholder equity, not annualized. This is down 47.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 2.2 percentage points.
Capital Allocation
BioScience Health Innovations Inc invested $50K in research and development in Q1 2026. This represents an increase of 32.5% from the same quarter a year earlier. Against the prior quarter it is down 47.7%.
Not reported for Q1 2026.
Not reported for Q1 2026.
BHICD Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'25 | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $751K-38.8% | $1.6M+157.7% | $1.1M+97.5% | $1.8M+357.5% | $1.2M+342.0% | $610K+101.0% | $573K+198.2% | $384K+453.0% |
| Cost of Revenue | $265K-19.8% | $1.0M+269.0% | $433K+192.2% | $683K+825.5% | $331K+672.5% | $271K+304.1% | $148K+365.8% | $74K+676.9% |
| Gross Profit | $486K-45.8% | $572K+68.7% | $698K+64.4% | $1.1M+246.2% | $896K+281.7% | $339K+43.3% | $425K+164.9% | $310K+417.6% |
| R&D Expenses | $50K+32.5% | $95K | N/A | N/A | $38K+4563.4% | N/A | N/A | N/A |
| SG&A Expenses | $626K+44.3% | $656K+118.6% | $577K+67.0% | $540K+142.6% | $434K+55.8% | $300K+13.3% | $345K+64.2% | $223K+60.5% |
| Operating Income | -$230K-153.9% | -$157K-1673.5% | -$9K-115.6% | $458K+516.7% | $427Kn/m | $10Kn/m | $56Kn/m | $74Kn/m |
| Income Tax | N/A | N/A | N/A | N/A | N/A | $0 | $0n/m | N/A |
| Net Income | -$230K-153.9% | -$234K-2446.4% | -$9K-115.6% | $458K+516.7% | $427Kn/m | $10Kn/m | $56Kn/m | $74Kn/m |
| EPS (Basic) | -$0.02 | N/A | $0.00 | $0.01n/m | $0.01n/m | N/A | $0.01 | $0.00 |
| EPS (Diluted) | -$0.02 | N/A | $0.00 | $0.01n/m | $0.01n/m | N/A | $0.01 | $0.00 |
| Diluted Shares (Avg) | 11M | N/A | 11M | 44M+5.5% | 44M+7.1% | N/A | 11M | 42M |
Not reported in any period shown, so not listed: EBITDA, Interest Expense.
BHICD Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'25 | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $2.3M+67.0% | $1.7M+95.4% | $2.1M+397.1% | $2.1M+863.2% | $1.4M+801.1% | $874K+835.7% | $416K+337.7% | $214K+239.2% |
| Current Assets | $2.2M+63.9% | $1.6M+83.9% | $2.0M+388.0% | $2.0M+829.5% | $1.3M+764.9% | $848K+807.8% | $409K+330.3% | $214K+239.2% |
| Cash & Equivalents | $1.1M+11.3% | $662K-0.1% | $1.1M+241.9% | $1.3M+802.9% | $1.0M+1006.5% | $663K+3343.8% | $333K+693.6% | $144K+374.7% |
| Inventory | $874K+305.4% | $336K+476.7% | $758K+1694.0% | $249K+512.1% | $216K+433.5% | $58K+54.7% | $42K+23.1% | $41K+156.5% |
| Accounts Receivable | $78K-16.2% | $399K+298.1% | $63K+98.1% | $390K+1311.6% | $93K+336.0% | $100K+175.1% | $32K+70.5% | $28K+74.7% |
| Total Liabilities | $646K+385.8% | $230K+496.3% | $356K+681.9% | $338K+1277.6% | $133K+232.8% | $39K-61.5% | $46K-47.3% | $25K-79.1% |
| Total Equity | $1.7M+33.5% | $1.5M+76.9% | $1.7M+362.1% | $1.7M+809.5% | $1.3M+998.8% | $835Kn/m | $370K+4204.6% | $189Kn/m |
| Retained Earnings | $71K-17.1% | $301Kn/m | $535Kn/m | $543Kn/m | $86Kn/m | -$341Kn/m | -$351Kn/m | -$407Kn/m |
Not reported in any period shown, so not listed: Short-Term Investments, Long-Term Investments, Goodwill, Current Liabilities, Non-Current Liabilities, Long-Term Debt.
BHICD Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'25 | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$552K-268.2% | -$101Kn/m | -$340K-751.8% | $285K+311.3% | $328Kn/m | -$50Kn/m | $52Kn/m | $69Kn/m |
| Investing Cash Flow | $0n/m | -$11Kn/m | $0n/m | -$16Kn/m | -$30Kn/m | -$19Kn/m | -$7Kn/m | $0n/m |
| Financing Cash Flow | $1.0M+1433.2% | -$366K-191.8% | $180K+25.2% | $2Kn/m | $68K-44.5% | $399K+1082.5% | $144K+75.6% | -$18K-113.5% |
Not reported in any period shown, so not listed: Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
BHICD Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'25 | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 64.7%-8.4pp | 36.4%-19.2pp | 61.7%-12.4pp | 61.1%-19.6pp | 73.0%-11.5pp | 55.6%-22.3pp | 74.1%-9.3pp | 80.8%-5.5pp |
| Operating Margin | -30.6%-65.4pp | -10.0%-11.6pp | -0.8%-10.6pp | 26.0%+6.7pp | 34.8%+54.0pp | 1.6%+14.3pp | 9.8%+39.6pp | 19.3% |
| Net Margin | -30.6%-65.4pp | -14.8%-16.5pp | -0.8%-10.6pp | 26.0%+6.7pp | 34.8%+54.0pp | 1.6%+14.3pp | 9.8%+39.6pp | 19.3% |
| Return on Equity | -13.7%-47.5pp | -15.8%-17.0pp | -0.5%-15.7pp | 26.6%-12.6pp | 33.8%+80.3pp | 1.2% | 15.2%+679.5pp | 39.3% |
| Return on Assets | -9.9%-40.5pp | -13.7%-14.8pp | -0.4%-13.9pp | 22.3%-12.5pp | 30.6%+65.1pp | 1.1%+42.2pp | 13.5%+73.7pp | 34.8%+170.2pp |
| Liabilities-to-Equity | 0.38+0.3x | 0.16+0.1x | 0.21+0.1x | 0.20+0.1x | 0.11-0.2x | 0.05 | 0.12-9.9x | 0.13 |
| Asset Turnover | 0.32-0.6x | 0.92+0.2x | 0.55-0.8x | 0.85-0.9x | 0.88-0.9x | 0.70-2.6x | 1.38-0.6x | 1.80+0.7x |
Not reported in any period shown, so not listed: Current Ratio, Debt-to-Equity, FCF Margin.
Where BioScience Health Innovations Inc Ranks
Frequently Asked Questions
BioScience Health Innovations Inc (BHICD) reported $5.7M in total revenue for fiscal year 2025. This represents a 208.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
BioScience Health Innovations Inc (BHICD) revenue grew by 208.3% year-over-year, from $1.8M to $5.7M in fiscal year 2025.
No, BioScience Health Innovations Inc (BHICD) reported a net loss of $15K over the trailing 12 months to March 31, 2026. In fiscal year 2025 it reported a net income of $642K, with a net profit margin of 11.3%.
BioScience Health Innovations Inc (BHICD) had a gross margin of 57.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
BioScience Health Innovations Inc (BHICD) had an operating margin of 12.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
BioScience Health Innovations Inc (BHICD) had a net profit margin of 11.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
BioScience Health Innovations Inc (BHICD) has a return on equity of 43.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
BioScience Health Innovations Inc (BHICD) generated $172K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
BioScience Health Innovations Inc (BHICD) had $1.7M in total assets as of fiscal year 2025, including both current and long-term assets.
BioScience Health Innovations Inc (BHICD) invested $38K in research and development during fiscal year 2025.
BioScience Health Innovations Inc (BHICD) had a liabilities-to-equity ratio of 0.16 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
BioScience Health Innovations Inc (BHICD) had a return on assets of 37.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
BioScience Health Innovations Inc (BHICD) has a Piotroski F-Score of 5 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
BioScience Health Innovations Inc (BHICD) has an earnings quality ratio of 0.27x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.